As unusual as this is in Phase 1, if the secondary doesn't place at a financially sufficient number, the very remote possibility of joint venture might be forced upon the company, their earlier denials, notwithstanding?
If the phase 1 results are truly as incredible as some suggest, and if our Board and advisors are so 'connected' and held in such high regard in the biotech world, then perhaps they might be able to facilitate a JV, as historically premature as this may be?
News 
Market Data 
Discover 
AI
